[January 18, 2013]

Research and Markets: PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update

Research and Markets (http://www.researchandmarkets.com/research/5g46lw/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update" to their offering.

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

French physicians included in this report may follow guidelines such as ACR, but also follow their own clinical experience to treat RA patients. In France, about 29% of referrals of patients presenting in any stage come from PCPs; however, other specialists including orthopedic surgeons are high referrers as well. Also, most people seeking treatment are 55 years and olde. Within this age group, females outnumber the males by a small margin compared with the younger age groups.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the France including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in France from 2011 to 2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the France rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in France

- Obtain sales forecast from 2011-2022 in France

Product Profiles - Major Brands

- Enbrel (etanercept)

- Humira (adalimumab)

- Remicade (infliximab)

- Simponi (golimumab)

- Cimzia (certolizumab pegol)

- Orencia (abatacept)

- Actemra/RoActemra (tocilizumab)

- Rituxan/MabThera (rituximab)

- Methotrexate Sodium (numerous generic names)

Promising Drugs in Clinical Development

- Tofacitinib (CP-690550)

- Tabalumab (LY2127399)

- Fostamatinib (previously R788)

- RAVAX

- Secukinumab (AIN457)

- Masitinib (AB101)

- Baricitinib (formerly LY3009104/INCB28050)

- Sarilumab (REGN88/SAR153191)

- Sirukumab (CNTO 136)

For more information visit http://www.researchandmarkets.com/research/5g46lw/pharmapoint

Source (News - Alert): GlobalData

[ Back To Technology News's Homepage ]